This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/chebi/
n21http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/pharmgkb/
n10http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/pdb/
admshttp://www.w3.org/ns/adms#
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00166/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00166
rdf:type
n5:Drug
n5:description
A vitamin-like antioxidant. [PubChem]
n5:generalReferences
# Perham RN: Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. Annu Rev Biochem. 2000;69:961-1004. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10966480 # REED LJ, DeBUSK BG, GUNSALUS IC, HORNBERGER CS Jr: Crystalline alpha-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase. Science. 1951 Jul 27;114(2952):93-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14854913
n5:group
approved nutraceutical
n5:indication
For nutritional supplementation, also for treating dietary shortage or imbalance.
owl:sameAs
n10:DB00166 n14:DB00166
dcterms:title
Lipoic Acid
adms:identifier
n4:LPA n12:PA164776929 n13:Lipoic_Acid n17:DB00166 n18:C00725 n19:16494 n22:D00086
n5:mechanismOfAction
Lipoic Acid is generally involved in oxidative decarboxylations of keto acids and is presented as a growth factor for some organisms. Lipoic acid exists as two enantiomers, the R-enantiomer and the S-enantiomer. Normally only the R-enantiomer of an amino acid is biologically active, but for lipoic acid the S-enantiomer assists in the reduction of the R-enantiomer when a racemic mixture is given. Some recent studies have suggested that the S-enantiomer in fact has an inhibiting effect on the R-enantiomer, reducing its biological activity substantially and actually adding to oxidative stress rather than reducing it. Furthermore, the S-enantiomer has been found to reduce the expression of GLUT-4s in cells, responsible for glucose uptake, and hence reduce insulin sensitivity.
n5:packager
n6:271B4FB3-363D-11E5-9242-09173F13E4C5 n6:271B4FB1-363D-11E5-9242-09173F13E4C5 n6:271B4FB2-363D-11E5-9242-09173F13E4C5 n6:271B4FAF-363D-11E5-9242-09173F13E4C5 n6:271B4FB0-363D-11E5-9242-09173F13E4C5
n5:synonym
alpha-Liponsaeure 5-[3-(1,2-dithiolanyl)]pentanoic acid Acetate-replacing factor α-lipoic acid 5-(1,2-dithiolan-3-yl)valeric acid 6-thioctic acid Lipoic acid 5-(dithiolan-3-yl)valeric acid 6,8-thioctic acid 6-thiotic acid 1,2-dithiolane-3-pentanoic acid Thioctsaeure Thioctic acid 1,2-dithiolane-3-valeric acid Thioktsaeure Biletan alpha-Lipoic acid liponic acid 6,8-thiotic acid Thioctansaeure
n5:synthesisReference
Joachim Paust, Peter Eckes, Wolfgang Siegel, Friedhelm Balkenhohl, Walter Dobler, Michael Hullmann, "Preparation of R/S-.gamma.-lipoic acid or R/S-.alpha.-lipoic acid." U.S. Patent US5489694, issued July, 1961.
n20:hasConcept
n21:M0012565
n5:IUPAC-Name
n8:271B4FBC-363D-11E5-9242-09173F13E4C5
n5:InChI
n8:271B4FC2-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n8:271B4FC1-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B4FBE-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n8:271B4FBF-363D-11E5-9242-09173F13E4C5
n5:SMILES
n8:271B4FC0-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n8:271B4FD1-363D-11E5-9242-09173F13E4C5 n8:271B4FBA-363D-11E5-9242-09173F13E4C5
n5:logP
n8:271B4FB8-363D-11E5-9242-09173F13E4C5 n8:271B4FBB-363D-11E5-9242-09173F13E4C5 n8:271B4FD4-363D-11E5-9242-09173F13E4C5
n5:logS
n8:271B4FB9-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:A16AX01
n5:H-Bond-Acceptor-Count
n8:271B4FC8-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n8:271B4FC9-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n8:271B4FC3-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n8:271B4FC4-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n8:271B4FC6-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n8:271B4FC5-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n8:271B4FC7-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
62-46-4
n5:category
n5:containedIn
n7:271B4FB6-363D-11E5-9242-09173F13E4C5 n7:271B4FB7-363D-11E5-9242-09173F13E4C5 n7:271B4FB4-363D-11E5-9242-09173F13E4C5 n7:271B4FB5-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n8:271B4FCD-363D-11E5-9242-09173F13E4C5
n5:Boiling-Point
n8:271B4FD3-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n8:271B4FCF-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n8:271B4FD0-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n8:271B4FD2-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n8:271B4FCC-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n8:271B4FCB-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n8:271B4FCE-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n8:271B4FBD-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n8:271B4FCA-363D-11E5-9242-09173F13E4C5